Vancouver, Canada-based mostly regenerative medication firm NervGen Pharma (TSXV: NGEN) introduced the appointment of Paul Brennan as president and chief government efficient instantly, changing Dr. Ernest Wong, who will proceed to help the corporate as an advisor formally.
Mr. Brennan has additionally has appointed as a member of NervGen’s board of administrators. The corporate additionally introduced the appointment of Lloyd Mackenzie within the newly-created place of chief working officer, additionally efficient instantly.
“We’re very excited concerning the addition of Paul Brennan and Lloyd Mackenzie to the NervGen crew as we proceed to construct a world-leading firm creating new therapies for spinal twine damage and neurodegenerative illnesses,” acknowledged Invoice Radvak, NervGen’s govt chairman.
“As an advisor to the board of administrators on enterprise growth and technique, Paul was instrumental in NervGen launching initiatives for each several sclerosis and Alzheimer’s illness indications on our know-how platform. Lloyd has a deep degree of experience in drug growth and can play a crucial function in overseeing the progress of our lead product, NVG-291,” Mr. Radvak added.
Mr. Brennan has held quite a lot of government positions inside biotech, together with Eupraxia Pharmaceuticals, Aquinox Pharmaceuticals, Arbutus Biopharma (previously Tekmira Prescribed drugs), Altair Therapeutics, Aspreva Pharmaceuticals, and AnorMED. Mr. Brennan performed main roles within the sale of Aspreva to Vifor Pharma for $915 million, the sale of AnorMED to Genzyme for $580 million, and the merger of Tekmira and OnCore Biopharma to kind Arbutus Biopharma, valued at over $1 billion on the day of the transaction. Mr. Brennan has additionally served in senior enterprise improvement and regulatory affairs roles with AstraZeneca, working in Sweden, the UK, and Canada.